Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
TORRENT PHARMA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
TORRENT PHARMA Mar-23 |
TEVA PHARMA Dec-13 |
TORRENT PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,723 | 3,484 | - | |
Low | Rs | 1,243 | 3,026 | - | |
Sales per share (Unadj.) | Rs | 284.2 | 1,999.3 | - | |
Earnings per share (Unadj.) | Rs | 36.8 | 124.9 | - | |
Cash flow per share (Unadj.) | Rs | 57.7 | 286.5 | - | |
Dividends per share (Unadj.) | Rs | 22.00 | 109.33 | - | |
Avg Dividend yield | % | 1.5 | 3.4 | 44.2% | |
Book value per share (Unadj.) | Rs | 183.1 | 2,220.8 | - | |
Shares outstanding (eoy) | m | 338.45 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.2 | 1.6 | 320.4% | |
Avg P/E ratio | x | 40.3 | 26.1 | 154.6% | |
P/CF ratio (eoy) | x | 25.7 | 11.4 | 226.3% | |
Price / Book Value ratio | x | 8.1 | 1.5 | 552.4% | |
Dividend payout | % | 59.8 | 87.5 | 68.3% | |
Avg Mkt Cap | Rs m | 501,779 | 2,760,189 | 18.2% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 16,777 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,721.8 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,356.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 96,202 | 1,695,406 | 5.7% | |
Other income | Rs m | 632 | 0 | - | |
Total revenues | Rs m | 96,834 | 1,695,406 | 5.7% | |
Gross profit | Rs m | 28,240 | 464,288 | 6.1% | |
Depreciation | Rs m | 7,066 | 137,041 | 5.2% | |
Interest | Rs m | 3,334 | 33,301 | 10.0% | |
Profit before tax | Rs m | 18,472 | 293,946 | 6.3% | |
Minority Interest | Rs m | 0 | 1,335 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,960 | -0.0% | |
Tax | Rs m | 6,019 | -3,589 | -167.7% | |
Profit after tax | Rs m | 12,452 | 105,911 | 11.8% | |
Gross profit margin | % | 29.4 | 27.4 | 107.2% | |
Effective tax rate | % | 32.6 | -1.2 | -2,669.1% | |
Net profit margin | % | 12.9 | 6.2 | 207.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 53,137 | 1,145,071 | 4.6% | |
Current liabilities | Rs m | 54,473 | 998,599 | 5.5% | |
Net working cap to sales | % | -1.4 | 8.6 | -16.1% | |
Current ratio | x | 1.0 | 1.1 | 85.1% | |
Inventory Days | Days | 15 | 91 | 17.1% | |
Debtors Days | Days | 7 | 96 | 7.7% | |
Net fixed assets | Rs m | 91,390 | 553,757 | 16.5% | |
Share capital | Rs m | 1,692 | 4,173 | 40.6% | |
Net worth | Rs m | 61,981 | 1,883,275 | 3.3% | |
Long term debt | Rs m | 24,962 | 866,899 | 2.9% | |
Total assets | Rs m | 144,682 | 3,874,547 | 3.7% | |
Interest coverage | x | 6.5 | 9.8 | 66.5% | |
Debt to equity ratio | x | 0.4 | 0.5 | 87.5% | |
Sales to assets ratio | x | 0.7 | 0.4 | 152.0% | |
Return on assets | % | 10.9 | 3.6 | 303.7% | |
Return on equity | % | 20.1 | 5.6 | 357.2% | |
Return on capital | % | 25.1 | 4.9 | 508.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 23,681 | 270,160 | 8.8% | |
From Investments | Rs m | -24,153 | -95,729 | 25.2% | |
From Financial Activity | Rs m | 774 | -324,075 | -0.2% | |
Net Cashflow | Rs m | 1,101 | -149,644 | -0.7% |
Compare TORRENT PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare TORRENT PHARMA With: SHAMROCK IND MAKERS LAB. HIKAL. PHARMAIDS PH SUVEN PHARMACEUTICALS
On Friday, Indian share markets traded on a positive note throughout the trading session and ended higher.